October 11, 2018 / 5:53 AM / 6 days ago

BRIEF- Mithra Pharmaceuticals Provides Update On Its Key Programmes

Oct 11 (Reuters) - MITHRA PHARMACEUTICALS SA:

* US/CANADA PHASE III ARM OF ESTELLE® ORAL CONTRACEPTION DUE TO COMPLETE IN Q4 2018

* PREPARATIONS FOR COMPREHENSIVE PHASE III TRIAL OF DONESTA® ARE UNDERWAY, REGULATORY SUBMISSION IS EXPECTED IN H2 2019

* FURTHER MARKETING AUTHORISATIONS OBTAINED FOR MYRING™

* CONTINUES TO HAVE STRONG CASH POSITION, WITH CAPACITY TO MAXIMIZE POTENTIAL OF ITS LEAD PRODUCTS AND PIPELINE

Source text: bit.ly/2y8my9N

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below